Skip to main content
Shahky Early Access Program Now Available—Sign-up to Learn More
Shahky Early Access Program Now Available—Sign-up to Learn More
 

June 25, 2018

Bio-Techne To Acquire Exosome Diagnostics, Inc.

June 13, 2018

Exosome Diagnostics Achieves ISO 13485:2016 Certification

May 22, 2018

Exosome Diagnostics Announces Bladder Cancer Surveillance Panel: The First Liquid Biopsy Designed Entirely By Artificial Intelligence (AI)

May 17, 2018

Exosome Diagnostics’ Second Prospective Validation Study of EPI to be Highlighted at American Urological Association (AUA) Annual Meeting Press Briefing in San Francisco, CAMay 15, 2018

May 15, 2018

Exosome Diagnostics Presents Breakthrough Data Highlighting Tumor Derived RNA in Biofluids at the International Society for Extracellular Vesicles in Spain

May 9, 2018

Exosome Diagnostics Continues to Expand Coverage Reach for its EPI Test

May 8, 2018

Exosome Diagnostics Expands National Sales Team after Blockbuster Quarter with its Flagship Diagnostic, ExoDx Prostate®(IntelliScore) (EPI) Test

April 17, 2018

Exosome Diagnostics Obviates Tissue Biopsies

March 21, 2018

Exosome Diagnostics Appoints Accomplished Urologist, Grannum Sant, MD, FRCS, FACS, as Head of Medical Affairs

March 20, 2018

Exosome Diagnostics Announces Publication of a Highly Sensitive Exosome Based Liquid Biopsy Test for EGFR T790M Mutations in Plasma from Non-Small Cell Lung Cancer Patients

March 13, 2018

Exosome Diagnostics Partners with Intezyne to Develop Exosomal RNA-based Assay for Novel Cancer Resistance Pathway (CRP) Inhibitor

February 23, 2018

Exosome Diagnostics Expands its Coverage Reach for EPI to an Additional 82 Million Covered Lives in the United States

February 1, 2018

Exosome Diagnostics Significantly Expands Access and Coverage for its EPI Prostate Cancer Test through Agreement with FedMed 

UPCOMING EVENTS

View more News and Events

Now available to Heathcare Providers for Clinical Use: The Industry’s First Exosome-Based Liquid Biopsy Tests

Order Here

The Industry’s First RNA-Based Liquid Biopsies

We are bringing the first exosome-based diagnostics to market. Learn more about our Laboratory Developed Tests, which will be analyzed in our CLIA-certified laboratory: